These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7515649)

  • 21. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.
    Jaksic B; Brugiatelli M; Krc I; Losonczi H; Holowiecki J; Planinc-Peraica A; Kusec R; Morabito F; Iacopino P; Lutz D
    Cancer; 1997 Jun; 79(11):2107-14. PubMed ID: 9179056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice].
    van Agthoven M; Wittebol S; Budel LM; Uyl-de Groot CA; Kramer MH
    Ned Tijdschr Geneeskd; 2004 Jan; 148(2):88-93. PubMed ID: 14753131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of CHEP and CHOP chemotherapy in the management of non-Hodgkin's lymphoma].
    Chen J; Wang Z
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):209-11. PubMed ID: 10920899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.
    Miller TP; Dahlberg S; Cassady JR; Adelstein DJ; Spier CM; Grogan TM; LeBlanc M; Carlin S; Chase E; Fisher RI
    N Engl J Med; 1998 Jul; 339(1):21-6. PubMed ID: 9647875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylprednisolone, etoposide, vindesine, and chlorambucil (PEEC) alone or alternating with CHOP as initial or salvage therapy for non-Hodgkin's lymphoma.
    Leonard RC; Lucraft HH; Proctor SJ; Allan NC; Dawson AA; Leonard RC; Lucraft HH; McGillivray JB; Parker AC; Prescott RJ
    Scott Med J; 1988 Dec; 33(6):360-2. PubMed ID: 3245016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study.
    Yahalom J; Varsos G; Fuks Z; Myers J; Clarkson BD; Straus DJ
    Cancer; 1993 Apr; 71(7):2342-50. PubMed ID: 8453557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma].
    Yuan ZY; Xu RH; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):393-6. PubMed ID: 12703996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
    Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
    Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis.
    Meusers P; Engelhard M; Bartels H; Binder T; Fülle HH; Görg K; Gunzer U; Havemann K; Kayser W; König E
    Hematol Oncol; 1989; 7(5):365-80. PubMed ID: 2670728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical analysis of 282 patients with non-Hodgkin's lymphoma].
    Chen SP; Wu DS; Zhao XL
    Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):237-9. PubMed ID: 14653077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
    Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D
    J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
    J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial.
    Ezzat AA; Ibrahim EM; Stuart RK; Ajarim D; Bazarbashi S; El-Foudeh MO; Rahal M; Al-Sayed A; Berry J
    Med Oncol; 2000 Feb; 17(1):39-46. PubMed ID: 10713659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma.
    Fisher RI
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S42-6. PubMed ID: 9272133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results.
    Khaled HM; Zekri ZK; Mokhtar N; Ali NM; Darwish T; Elattar I; Gaafar R; Moawad MS
    Ann Oncol; 1999 Dec; 10(12):1489-92. PubMed ID: 10643541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of treating stage III and IV malignant non-Hodgkin's lymphomas (NHL).
    Jahn H; Ruffert K; Syrbe G; Kühn R; Jorke D
    Arch Geschwulstforsch; 1988; 58(2):113-20. PubMed ID: 2454087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group.
    Meerwaldt JH; Carde P; Somers R; Thomas J; Kluin-Nelemans JC; Bron D; Noordijk EM; Cosset JM; Bijnens L; Teodorovic I; Hagenbeek A
    Ann Oncol; 1997; 8 Suppl 1():67-70. PubMed ID: 9187434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone.
    Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Flores A; Millá F; Feliu E
    Br J Haematol; 2001 Mar; 112(4):909-15. PubMed ID: 11298585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CHOP chemotherapy of intermediate and high-grade non-Hodgkin's lymphoma.
    Llanos M; Tabernero J; Brunet J; Amenedo M; Pallares C; de Andres L; Lopez JJ
    Acta Oncol; 1994; 33(8):935-9. PubMed ID: 7818928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma.
    Zinzani PL; Martelli M; Storti S; Musso M; Cantonetti M; Leone G; Cajozzo A; Papa G; Iannitto E; Perrotti A
    Leuk Lymphoma; 1995 Oct; 19(3-4):329-35. PubMed ID: 8535227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.